-
O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia
2026-09-05
The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that connects trophoblast ferroptosis, iron uptake, syncytialization, and preeclampsia-associated pregnancy outcomes. Its combination of O-GlcNAc modification proteomics, mechanistic ubiquitination analysis, trophoblast models, and mouse experiments provides a framework for testing how protein O-GlcNAc modification regulates placental stress.
-
Surrogate BBB Model Improves CNS Permeability Screening
2026-09-05
Hu and colleagues developed a high-throughput LLC-PK1-MOCK/MDR1 Transwell model that combines passive permeability measurement, P-glycoprotein efflux analysis, and correction for lysosomal trapping. Across 41 compounds, the platform correlated in vitro transport with unbound brain distribution and achieved no more than twofold prediction error in its validation set, supporting its use for early CNS drug screening.
-
Steroid Lysis of Protoplasts: Mechanistic Insights
2026-09-04
Smith and Shay used osmotically fragile Sarcina lutea protoplasts to separate direct membrane damage from effects requiring an intact bacterial cell wall. Their antagonist and stabilizer experiments showed that steroid-associated lysis was strongly modified by polyamines, metal ions, uranyl nitrate, and surfactants, supporting a primarily membrane-directed antimicrobial mechanism.
-
Diethylmaleate Workflows for GST and Redox Studies
2026-09-04
Diethylmaleate provides a practical way to perturb glutathione-dependent defenses and connect GST activity with ROS, apoptosis, and stress tolerance. This guide translates insecticide-resistance findings into reproducible cellular, toxicology, and redox-regulation workflows while emphasizing controls, solvent discipline, and assay troubleshooting.
-
Cell Counting Kit-8 Plus in Airway Translation
2026-09-03
A mechanistic and strategic guide to using Cell Counting Kit-8 Plus as a viability gatekeeper in air–liquid interface models, pollutant studies, cytotoxicity testing, and translational drug screening.
-
Apigenin: From HDAC Mechanism to Translation
2026-09-03
Apigenin links HDAC inhibition, oxidative stress, DNA damage, and context-dependent apoptosis across malignant mesothelioma and neurodegeneration models. This thought-leadership guide translates those findings into practical assay strategy while defining the evidence gaps that matter for translational development.
-
Erlotinib, SCUBE3, and the Next EGFR Map
2026-09-02
Erlotinib (NSC 718781) is more than an EGFR kinase inhibitor: it is a precise mechanistic probe for testing how receptor signaling intersects with secreted drivers of resistance and immune suppression. This translational perspective connects EGFR autophosphorylation inhibition with the emerging SCUBE3–EGFR axis and provides practical guidance for biochemical, cellular, and tumor microenvironment studies.
-
WP1066: JAK2/STAT3 Inhibitor Assay Workflows
2026-09-02
WP1066 is a cell-permeable JAK2/STAT3 inhibitor for linking pathway suppression to cancer-cell growth, apoptosis, and angiogenic behavior. This guide translates product specifications and a macrophage-focused bone-regeneration study into practical assay design, controls, and troubleshooting decisions.
-
BHQ for SERCA and Calcium Signaling Research
2026-09-01
BHQ provides a practical way to perturb SERCA-dependent calcium storage, enabling mechanistic studies from ER calcium depletion to hematopoietic stem cell mobilization. Its value is greatest when calcium imaging, surface-marker analysis, viability testing, and pathway validation are combined rather than interpreted as a single endpoint.
-
MEK1/2, c-Myc:MAX, and TERT in hESC
2026-09-01
The reference preprint identifies a regulatory connection in which MEK1/2–ERK signaling cooperates with c-Myc:MAX to keep the TERT promoter active in human embryonic stem cells. Its inhibitor, chromatin immunoprecipitation, and rescue experiments link loss of kinase or c-Myc:MAX activity to PRC2-associated repression, providing a mechanistic framework for studying telomerase control in pluripotent cells.
-
PTX3–TLR4/NF-κB/FGF21 Axis in Steroid ONFH
2026-08-31
The reference study identifies reduced pentraxin 3 (PTX3) as a molecular feature of glucocorticoid-induced osteonecrosis of the femoral head and defines a protective PTX3–TLR4/NF-κB/FGF21 signaling axis. By combining cellular, genetic, pharmacological, and in vivo approaches, the work connects PTX3 supplementation with improved osteogenesis and reduced apoptosis, while positioning FGF21 suppression as a key downstream event.
-
BIIE 0246 and the NPY Y2R Axis
2026-08-30
BIIE 0246 offers a selective way to interrogate neuropeptide Y Y2 receptor signaling across presynaptic, gastrointestinal, feeding, and behavioral models. This thought-leadership article connects Y2R mechanism to the adipose-neural axis while distinguishing established evidence from translational hypotheses.
-
EZ Cap™ Firefly Luciferase mRNA as a Delivery Probe
2026-08-29
EZ Cap™ Firefly Luciferase mRNA can function as more than a reporter: it is a practical probe for separating mRNA delivery, endosomal release, and translation performance. This article connects Cap 1 and poly(A) design with ionizable-lipid screening and assay interpretation.
-
Q7j and HER2-EMT Control in Breast Cancer
2026-08-29
Li et al. used a Mubritinib-inspired fragment to synthesize 32 HER2 inhibitor candidates and identified Q7j as a potent compound with anti-migratory activity in HER2-positive breast cancer models. The study connects HER2 phosphorylation control with EMT-associated protein changes and provides a useful framework for evaluating kinase inhibitors beyond proliferation assays.
-
Canagliflozin and Proximal-Tubule Mitochondria
2026-08-28
The reference study shows that canagliflozin improves mitochondrial organization and bioenergetic performance in proximal tubular cells from hypertensive–diabetic mice, with stronger functional effects in males than females. Its findings support a kidney-protective mechanism that extends beyond glucose lowering and provides a useful framework for studying mitochondrial remodeling in diabetic kidney disease.